International Strategies for Tropical Disease Treatments - Experiences with Praziquantel - EDM Research Series No. 026
(1998; 113 pages) View the PDF document
Table of Contents
View the documentAbstract
View the documentAcknowledgments
View the documentInformation on authors
View the documentExchange rates used in the report
Open this folder and view contentsChapter 1: Policies for praziquantel*
Open this folder and view contentsChapter 2: Bayer & E. Merck: Discovery and development of praziquantel*
Open this folder and view contentsChapter 3: Shin Poong Pharmaceutical Co.: Process development in the Republic of Korea*
Open this folder and view contentsChapter 4: The Egyptian International Pharmaceutical Industries Co.: Praziquantel formulation*
Open this folder and view contentsChapter 5: The international supply of praziquantel*
Open this folder and view contentsChapter 6: Demand for praziquantel and national distribution*
Close this folderChapter 7: Prices and production costs of praziquantel*
View the documentThe price of praziquantel
View the documentProduction costs and pricing strategies of major producers
View the documentReferences
View the documentOther documents in the DAP Research Series
View the documentDAP Research Series No. 26
 

Chapter 7: Prices and production costs of praziquantel*

* By Ramesh Govindaraj, Michael R. Reich, and Karin Dumbaugh.

This chapter examines the prices of praziquantel in various market segments, and the production costs of praziquantel. The section on pricing traces changes in praziquantel prices over time, and presents data on: current prices at which praziquantel is purchased by bulk suppliers; prices obtained by developing countries through tenders; and prices at which the drug is sold by producers in the private market in developed and developing countries. The section on production costs discusses the costs of manufacturing praziquantel faced by the major producers, and their pricing strategies. The section also explores problems experienced by Bayer and E. Merck in competing in the international market with lower-priced producers, who have successfully used process patent laws to develop alternative (and much cheaper) processes for producing praziquantel.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: August 29, 2014